The global atrophic vaginitis treatment market garnered a market value of US$ 2.57 Billion in 2022 and is expected to accumulate a market value of US$ 6 Billion by registering a CAGR of 8% in the forecast period 2023 to 2033. Growth of the atrophic vaginitis treatment market can be attributed to increasing prevalence of the condition, the rising geriatric population, and the growing awareness about the importance of women's health. The market for atrophic vaginitis treatment registered a CAGR of 4.1% in the historical period 2018 to 2022
Atrophic vaginitis is a medical condition that occurs due to the thinning and inflammation of the vaginal walls, which is common in postmenopausal women. Atrophic vaginitis treatment market refers to the market for medications and therapies used to treat this condition.
The atrophic vaginitis treatment market includes a variety of products such as estrogen creams, vaginal moisturizers, and lubricants, among others. These products help to alleviate symptoms such as vaginal dryness, itching, and pain during intercourse.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 2.78 Billion |
| Anticipated Forecast Value (2033) | US$ 6 Billion |
| Projected Growth Rate (2023 to 2033) | 8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Atrophic vaginitis treatment reflected a value of 8% during the historical period, 2018 to 2022.
The market was driven by the increasing prevalence of atrophic vaginitis, the rising awareness of women's health, and the availability of effective treatment options. In addition, the increasing prevalence of atrophic vaginitis, the growing geriatric population, and the availability of new and innovative therapies is shaping the landscape for atrophic vaginitis treatment market.
Thus, the market for Atrophic vaginitis treatment is expected to register a CAGR of 4.1% in the forecast period 2023 to 2033.
Increasing prevalence of atrophic vaginitis along with rising awareness about women's health driving growth of market
The prevalence of atrophic vaginitis is increasing worldwide, especially in postmenopausal women. The condition affects approximately 50% of postmenopausal women, which is a significant population size. As the global population continues to age, the number of women affected by atrophic vaginitis is expected to increase. Women over the age of 65 are more likely to experience the condition.
There has been a growing awareness about the importance of women's health, leading to increased diagnosis and treatment of atrophic vaginitis. There are several effective treatment options available for atrophic vaginitis, such as estrogen creams, vaginal moisturizers, and lubricants. The availability of these treatments has increased demand for atrophic vaginitis treatment.
The increasing healthcare expenditure globally has led to increased access to healthcare services, including diagnosis and treatment of atrophic vaginitis.
Availability of Effective Treatment Options spurring growth of atrophic vaginitis treatment market
Estrogen Therapy: Estrogen therapy is one of the most effective treatments for atrophic vaginitis. It can be administered in the form of pills, creams, rings, or patches. Estrogen therapy can help to restore the vaginal tissues and alleviate symptoms such as vaginal dryness, itching, and pain during intercourse.
Vaginal Lubricants: Vaginal lubricants are used to reduce friction during intercourse and alleviate symptoms of vaginal dryness. They can be used alone or in combination with other treatments.
Vaginal Moisturizers: Vaginal moisturizers are used to hydrate and soothe the vaginal tissues. They can be used on a regular basis to alleviate symptoms of vaginal dryness.
Topical Estrogen Creams: Topical estrogen creams can be applied directly to the vaginal tissues to alleviate symptoms of atrophic vaginitis.
Osphena: Osphena is a non-estrogen prescription medication that can help alleviate symptoms of vaginal dryness and pain during intercourse.
Laser Therapy: Laser therapy is a new treatment option for atrophic vaginitis. It involves the use of laser technology to stimulate the growth of new tissue and improve the health of the vaginal tissues.
Principal Consultant
Side effects of hormone therapy along with cost of treatment derailing market growth
While hormone therapy is one of the most effective treatments for atrophic vaginitis, it can have potential side effects such as blood clots, stroke, and breast cancer. This can limit the use of hormone therapy, particularly in women who have a history of these conditions.
Despite growing awareness about women's health, many women may not be aware of the symptoms of atrophic vaginitis or the available treatment options. This can lead to underdiagnosis and undertreatment of the condition.
Some women may prefer to use alternative treatments such as herbal remedies or supplements, which may not have been adequately studied for their efficacy and safety in treating atrophic vaginitis. Some of the treatment options for atrophic vaginitis can be expensive, and not all women may have access to healthcare coverage that covers these costs.
Due to the intimate nature of the condition, some women may feel embarrassed or uncomfortable discussing their symptoms with their healthcare providers, which can lead to delays in diagnosis and treatment.
Availability of effective treatment favoring growth of market in North America
The North America atrophic vaginitis treatment market is a significant market, primarily driven by the high prevalence of the condition in the region. The market comprises the United States and Canada, which are expected to have a significant demand for atrophic vaginitis treatments.
The United States has a large population of postmenopausal women, which is the most susceptible group for atrophic vaginitis. As a result, the country has a significant demand for treatment options. The market is also supported by the presence of major pharmaceutical companies, such as Pfizer, Inc., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd, that offer a range of atrophic vaginitis treatments.
In addition, the increasing awareness about women's health and the availability of effective treatment options are expected to drive the growth of the North America atrophic vaginitis treatment market. Thus, North America is expected to possess 48% market share for atrophic vaginitis treatment market in 2023.
Presence of pharmaceutical companies boosting growth of market in Europe
The Europe atrophic vaginitis treatment market is a significant market, primarily driven by the high prevalence of the condition in the region. The market comprises the major countries in Europe, including the United Kingdom, Germany, France, Italy, Spain, and the rest of Europe.
The increasing aging population in Europe, particularly in Western Europe, is expected to contribute significantly to the growth of the market. Postmenopausal women, who are the most susceptible group for atrophic vaginitis, form a significant proportion of the aging population in Europe.
The market is also supported by the presence of major pharmaceutical companies that offer a range of atrophic vaginitis treatments, such as Pfizer, Inc., Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.
Overall, the Europe atrophic vaginitis treatment market is expected to grow at a steady rate, driven by the increasing prevalence of the condition and growing demand for effective treatment options. The market is also likely to benefit from ongoing initiatives to raise awareness about women's health and the availability of treatment options. Thus, Europe is expected to possess 43% market share for atrophic vaginitis treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Availability of different estrogen-based therapy driving the growth of segment
Estrogen-based therapy is one of the most effective treatment options for atrophic vaginitis because it addresses the underlying cause of the condition. Atrophic vaginitis is primarily caused by a decrease in estrogen levels in the body, which can lead to vaginal dryness, itching, burning, and pain during sexual intercourse. Estrogen therapy helps to restore estrogen levels, which can improve the health of the vaginal tissues and relieve symptoms.
There are several forms of estrogen-based therapy available for atrophic vaginitis, including vaginal creams, tablets, rings, and patches. These products deliver estrogen directly to the vaginal tissues, which can help to restore vaginal health and relieve symptoms such as vaginal dryness, itching, and discomfort.
Estrogen therapy has been shown to be safe and effective for the treatment of atrophic vaginitis in numerous clinical studies. It is generally well-tolerated, and side effects are usually mild and temporary. Thus, by therapy type, estrogen based therapy is expected to possess 53% market share for atrophic vaginitis treatment market.
Key players in the atrophic vaginitis treatment are Shionogi, Duchesnay, Hormos Medical, QuatRx Pharmaceuticals, Pantarhei Bioscience, Mithra Pharmaceuticals, AMAG Pharmaceuticals, Bayer HealthCare Pharmaceuticals Inc, Theramex, Endoceutics, Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 2.78 Billion |
| Market Value in 2033 | US$ 6 Billion |
| Growth Rate | CAGR of 8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The CAGR for the market is 8% until 2033.
From 2018 to 2022, the market expanded at a 4.1% CAGR.
North America to hold 48% market share in 2023.
Shionogi, Duchesnay and Hormos Medical are key players.
Innovative therapies and expanding aging population present growth prospects.
1. Executive Summary | Atrophic Vaginitis Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
5.3.1. Pelvic exam
5.3.2. Urine test
5.3.3. Acid balance test
5.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
6.3.1. Vaginal moisturizers
6.3.2. Water-based lubricants
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2023 to 2033
7.3.1. Estrogen based drugs
7.3.2. Non-estrogen based drugs
7.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Therapy Type, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacy
8.3.2. Online Pharmacy
8.3.3. Retail Pharmacy
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. MEA
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Diagnosis
10.2.3. By Treatment
10.2.4. By Therapy Type
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Diagnosis
10.3.3. By Treatment
10.3.4. By Therapy Type
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Diagnosis
11.2.3. By Treatment
11.2.4. By Therapy Type
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Diagnosis
11.3.3. By Treatment
11.3.4. By Therapy Type
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Diagnosis
12.2.3. By Treatment
12.2.4. By Therapy Type
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Diagnosis
12.3.3. By Treatment
12.3.4. By Therapy Type
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Diagnosis
13.2.3. By Treatment
13.2.4. By Therapy Type
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Diagnosis
13.3.3. By Treatment
13.3.4. By Therapy Type
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Diagnosis
14.2.3. By Treatment
14.2.4. By Therapy Type
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Diagnosis
14.3.3. By Treatment
14.3.4. By Therapy Type
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Diagnosis
15.2.3. By Treatment
15.2.4. By Therapy Type
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Diagnosis
15.3.3. By Treatment
15.3.4. By Therapy Type
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Diagnosis
16.2.3. By Treatment
16.2.4. By Therapy Type
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Diagnosis
16.3.3. By Treatment
16.3.4. By Therapy Type
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Diagnosis
17.1.2.2. By Treatment
17.1.2.3. By Therapy Type
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Diagnosis
17.2.2.2. By Treatment
17.2.2.3. By Therapy Type
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Diagnosis
17.3.2.2. By Treatment
17.3.2.3. By Therapy Type
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Diagnosis
17.4.2.2. By Treatment
17.4.2.3. By Therapy Type
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Diagnosis
17.5.2.2. By Treatment
17.5.2.3. By Therapy Type
17.5.2.4. By Distribution Channel
17.6. United kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Diagnosis
17.6.2.2. By Treatment
17.6.2.3. By Therapy Type
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Diagnosis
17.7.2.2. By Treatment
17.7.2.3. By Therapy Type
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Diagnosis
17.8.2.2. By Treatment
17.8.2.3. By Therapy Type
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Diagnosis
17.9.2.2. By Treatment
17.9.2.3. By Therapy Type
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Diagnosis
17.10.2.2. By Treatment
17.10.2.3. By Therapy Type
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Diagnosis
17.11.2.2. By Treatment
17.11.2.3. By Therapy Type
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Diagnosis
17.12.2.2. By Treatment
17.12.2.3. By Therapy Type
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Diagnosis
17.13.2.2. By Treatment
17.13.2.3. By Therapy Type
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Diagnosis
17.14.2.2. By Treatment
17.14.2.3. By Therapy Type
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Diagnosis
17.15.2.2. By Treatment
17.15.2.3. By Therapy Type
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Diagnosis
17.16.2.2. By Treatment
17.16.2.3. By Therapy Type
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Diagnosis
17.17.2.2. By Treatment
17.17.2.3. By Therapy Type
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Diagnosis
17.18.2.2. By Treatment
17.18.2.3. By Therapy Type
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Diagnosis
17.19.2.2. By Treatment
17.19.2.3. By Therapy Type
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Diagnosis
17.20.2.2. By Treatment
17.20.2.3. By Therapy Type
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Diagnosis
17.21.2.2. By Treatment
17.21.2.3. By Therapy Type
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Diagnosis
18.3.3. By Treatment
18.3.4. By Therapy Type
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Shionogi
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Duchesnay
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Hormos Medical
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. QuatRx Pharmaceuticals
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Pantarhei Bioscience
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Mithra Pharmaceuticals
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. AMAG Pharmaceuticals
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Bayer HealthCare Pharmaceuticals Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Theramex
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Endoceutics, Inc.
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Atrophic Vaginitis Treatment Market
